BiotechTube
Home/Pipeline/ESR1 Mutation Detection Assay

ESR1 Mutation Detection Assay

Breast Cancer

Assay Development/ValidationActive

Key Facts

Indication
Breast Cancer
Phase
Assay Development/Validation
Status
Active
Company
Stilla Technologies

About Stilla Technologies

Stilla Technologies, founded in 2016 and based in Paris, is a leader in multiplex digital PCR technology. The company's core innovation is the Nio® platform, which offers 7-color detection, continuous loading, and high sample throughput, addressing key limitations in traditional dPCR and qPCR. Its technology is applied in critical areas such as cancer mutation detection, CRISPR quality control, and viral vector analytics, serving academic, clinical, and biopharmaceutical customers. In 2024, Stilla Technologies was acquired by Bio-Rad Laboratories, significantly enhancing its global commercial reach and resources.

View full company profile

Therapeutic Areas

OncologyGenetic DisordersInfectious Diseases

Other Breast Cancer Drugs

DrugCompanyPhase
Antifibrotic Therapy ProgramMeCo DiagnosticsPre-clinical
inPROBE for HER2SDS OpticClinical Investigation
ACT‑BC1AnthrocellPreclinical
APA-1000 Breast Thermotherapy SystemMedifocusPhase III
Early‑Detection Breast Cancer ScreeningKarkinos HealthcareMarket
Unnamed Breast Cancer ProgramClick TherapeuticsPilot/Phase 2
Lerociclib (Lerocliclib)Chemogenics BioPharmaPhase 3
AT-017Asieris PharmaceuticalsNot Specified
CDK2 inhibitorAcelleraPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Maveropepimut-S (MVP-S)BioVaxysClinical Evaluation
Cannabics® BRST-33CNBX PharmaceuticalsDiscovery